Collegium (COLL) Q3 2025: Journay PM Revenue Jumps 46% as ADHD Franchise Accelerates

November 6, 2025 | By EarningsIQ Research

Collegium’s Q3 showcased a step-change in ADHD franchise momentum, with Journay PM’s prescription and revenue growth outpacing expectations and supporting a guidance raise. The pain portfolio’s resilience and margin-enhancing improvements further strengthened Collegium’s cash generation and balance sheet. Management’s capital deployment signals a disciplined, expansion-oriented playbook as the company eyes additional business development to extend its differentiated specialty portfolio.

Summary

• ADHD Franchise Outperformance: Journay PM’s prescription and revenue growth accelerated, validating commercial investments.
• Pain Portfolio Stability: Core pain brands delivered durable growth, supporting cash flow and capital flexibility.
• Capital Deployment Discipline: Management balances M&A, share buybacks, and debt reduction to fuel future expansion.

Performance Analysis

Collegium delivered record quarterly net product revenue and adjusted EBITDA, driven by outperformance in both its ADHD and pain portfolios. Journay PM, the company’s lead ADHD stimulant with once-daily evening dosing, generated a 20% year-over-year prescription increase and 46% revenue growth versus 2024 pro forma levels. The brand now comprises a significant and expanding share of Collegium’s top line, reflecting both increased demand and improved gross-to-net realization. Market share gains in the long-acting branded methylphenidate segment and a 22% increase in prescriber base highlight the brand’s penetration across pediatric and adult segments.

The pain portfolio—anchored by Belbuca, Xtampza ER, and the Nucynta franchise—delivered consistent double-digit revenue growth, with all three core medicines growing for the third consecutive quarter. Notably, Nucynta’s profitability benefited from rebate settlements and gross-to-net improvements, boosting margins. Operating cash flow remained robust, supporting $16.1 million in debt repayment and opportunistic share repurchases. Management raised full-year revenue and EBITDA guidance, citing confidence in the durability of both ADHD and pain franchises.

• Journay PM Leverage: Rapid prescription growth and improved reimbursement dynamics are driving top-line acceleration.
• Pain Franchise Durability: Sustained demand and payer stability reinforce the segment’s cash-generating foundation.
• Margin Expansion: Gross-to-net improvements and rebate settlements are enhancing overall profitability.

Collegium’s ability to drive simultaneous growth across both legacy and acquired assets demonstrates operational discipline and portfolio integration strength.

Executive Commentary

Strategic Positioning

1. ADHD Franchise Expansion

Journay PM’s differentiated evening dosing and all-day symptom control are resonating with prescribers and patients, as evidenced by a 6.3 percentage point market share gain and 22% growth in prescribers. Collegium’s expanded sales force and targeted digital campaigns, including a new partnership with Paris Hilton, are increasing awareness and driving new patient starts. The pediatric and adolescent segment remains the largest, but adult growth (29% YoY) signals a broadening opportunity.

2. Pain Portfolio Resilience

The pain segment—encompassing Belbuca, Xtampza ER, and Nucynta—continues to provide a stable and profitable base, with revenues up 11% year-over-year. Collegium’s payer strategy has secured broad coverage and exclusive formulary access for Xtampza ER, supporting both demand and gross-to-net optimization. Real-world evidence and continued medical education reinforce the brands’ differentiation in responsible pain management.

3. Capital Deployment and Portfolio Diversification

Management is executing a balanced capital allocation strategy: $25 million returned to shareholders via buybacks year-to-date, $16.1 million in debt repaid in Q3, and a stated willingness to lever up for the right business development opportunity. The focus remains on commercial or near-commercial assets in pain, CNS, or adjacent call-point synergies, with R&D risk deprioritized for now. The company’s net leverage is expected to fall below 1x by year-end, providing ample flexibility.

Key Considerations

Collegium’s Q3 results underscore the company’s transformation into a dual-engine specialty pharmaceutical platform, with both ADHD and pain franchises contributing to growth and margin expansion. Investors should focus on the following:

Key Considerations:

• Journay PM Commercial Traction: Prescription growth and prescriber expansion are translating into accelerating revenue and market share gains.
• Pain Franchise Stability: Revenue durability and payer stability reduce risk of near-term erosion, supporting cash flow visibility.
• Gross-to-Net Improvements: Seasonality, returns management, and favorable contracting are driving margin gains, particularly in ADHD and Nucynta.
• Business Development Optionality: Ample balance sheet capacity and a disciplined approach position Collegium to opportunistically expand its portfolio.

Risks

Collegium remains exposed to typical specialty pharma risks, including payer formulary shifts, generic erosion, and regulatory scrutiny of controlled substances. While management expects minimal negative payer changes in 2026, any adverse formulary action could impact volumes or pricing. Business development execution risk and integration challenges also loom, particularly as the company seeks to add new assets without overextending operational or financial resources.

Forward Outlook

For Q4 2025, Collegium guided to:

• Total product revenues in the range of $775 to $785 million for the full year
• Journay PM revenue of $145 to $150 million, with full-year gross-to-net in the mid-60% range
• Adjusted EBITDA of $460 to $470 million

Management highlighted several factors that will shape the next quarters:

• Continued momentum for Journay PM into 2026, with expanded sales force impact expected to ramp
• Pain franchise revenues expected to remain stable, with no major payer disruptions anticipated

Takeaways

Collegium’s Q3 confirms the company’s dual growth engine strategy is working, with both ADHD and pain franchises outperforming expectations and supporting a guidance raise.

• ADHD Platform Scaling: Journay PM’s prescription and revenue growth reinforce the brand’s potential as a long-term franchise driver, with commercial investments yielding early returns.
• Pain Portfolio as Cash Anchor: Sustained double-digit growth and payer stability ensure the legacy pain business remains a reliable source of cash for reinvestment.
• Capital Allocation Readiness: Collegium’s low leverage and balanced deployment approach position it to pursue further business development without compromising financial health.

Conclusion

Collegium’s Q3 marked a pivotal quarter, with ADHD and pain franchises both delivering above-market growth and profitability. The company’s disciplined execution, robust cash generation, and flexible capital deployment set the stage for further portfolio expansion and shareholder value creation into 2026.

Industry Read-Through

Collegium’s results highlight two key trends for specialty pharma: differentiated brands with clear clinical advantages can still drive significant growth in mature categories, and gross-to-net management remains a critical lever for margin expansion. For ADHD and pain management markets, payer stability and real-world evidence are increasingly important for sustaining branded product lifecycles. Competitors should note the impact of targeted commercial investment and digital engagement, as well as the value of maintaining balance sheet flexibility for opportunistic M&A in a consolidating landscape.

COLL Healthcare Specialty Pharma ADHD Pain Management Gross-to-Net Business Development